Thermo Fisher Scientific Inc. Plans Quarterly Dividend of $0.47 (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) declared a quarterly dividend on Thursday, July 9th. Stockholders of record on Tuesday, September 15th will be given a dividend of 0.47 per share by the medical research company on Thursday, October 15th. This represents a c) annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 15th.

Thermo Fisher Scientific has raised its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 8 consecutive years. Thermo Fisher Scientific has a payout ratio of 7.6% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Thermo Fisher Scientific to earn $27.18 per share next year, which means the company should continue to be able to cover its $1.88 annual dividend with an expected future payout ratio of 6.9%.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $523.58 on Friday. Thermo Fisher Scientific has a 12 month low of $403.36 and a 12 month high of $643.99. The firm has a market capitalization of $194.57 billion, a PE ratio of 28.78, a P/E/G ratio of 2.26 and a beta of 0.87. The company’s 50 day simple moving average is $477.01 and its 200 day simple moving average is $516.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the firm posted $5.15 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific will post 24.84 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Assetmark Inc. raised its stake in shares of Thermo Fisher Scientific by 22.9% during the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after purchasing an additional 7,023 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Thermo Fisher Scientific by 29.4% in the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after buying an additional 62,790 shares in the last quarter. North Dakota State Investment Board bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $7,505,000. EdgePoint Investment Group Inc. lifted its holdings in Thermo Fisher Scientific by 5.0% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 1,388,662 shares of the medical research company’s stock worth $673,529,000 after purchasing an additional 65,597 shares during the last quarter. Finally, Confluence Investment Management LLC boosted its position in Thermo Fisher Scientific by 14.2% during the fourth quarter. Confluence Investment Management LLC now owns 95,064 shares of the medical research company’s stock worth $55,085,000 after purchasing an additional 11,841 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.